stockrowRevolution Medicines, Inc.
RVMD Healthcare Biotechnology
Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.
- Revenue
- +1,188.7%
- EPS
- −18.0%
- Free cash flow
- −99.1%
- Total debt
- +322.7%
Quarter to September 2026, against a year earlier
Follow RVMD
Alert me
Revolution Medicines, Inc. (RVMD) Debt to equity
Revolution Medicines, Inc.'s debt to equity at the end of the quarter to 30 September 2026 was 0.0×, down 0.2× from fiscal 2025 (0.2×). Over the past ten years it has ranged from 0.0× (fiscal 2024) to 0.2× (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.0× and in line with the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.2× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.1× | (16.45%) |
| FY2021 | 0.1× | 64.16% |
| FY2020 | 0.1× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.4× | 112.45% |
| Mar 2026 | 0.2× | 13.67% |
| Dec 2025 | 0.2× | 2.49% |
| 29 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| ROIV Roivant Sciences Ltd. compare | 0.0× |
| ARGX argenex SE compare | 0.0× |
| RVMD Revolution Medicines, Inc. | 0.0× |
| INCY Incyte Corporation compare | 0.0× |
| BNTX BioNTech SE Sponsored ADR compare | 0.0× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 0.1× |
| INSM Insmed, Inc. compare | 0.8× |
| GMAB Genmab A/S Sponsored ADR compare | 0.9× |
| RPRX Royalty Pharma PLC compare | 0.9× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on RVMD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement